SEATTLE, Oct. 20, 2021 (GLOBE NEWSWIRE) According to Coherent Market Insights, the global charcot-marie-tooth disease market is estimated to be valued.
leading cause of non-traumatic lower extremity amputations in the United States, and approximately
14-24% of patients with diabetes who develop a foot ulcer will require an
amputation. Foot ulceration precedes
85% of diabetes-related amputations.
The gold standard for Diabetic Foot Ulcer treatment includes debridement of the wound, management of any infection, revascularization procedures when indicated, and off-loading of the ulcer.
Currently, the market is mainly dominated by
off-label generic drugs such as analgesics and anti-infectives,
around 78% of the current market is captured by these two classes of drugs.
There is only one drug,
Regranex (Becaplermin), which the FDA has approved.
Regranex gel uses a Platelet-derived growth factor (PDGF) for the Diabetic Neuropathic Ulcer treatment formulated to act as a first-line treatment following effective ulcer care. The US FDA had approved the biologics license application of Becaplermin (OMJ Pharmaceuticals, Inc
Wacker Chemie AG: WACKER Strengthens Biologics Business by Acquiring US-Based Plasmid DNA Manufacturer Genopis 03.02.2021 / 00:15
WACKER TAKES OVER GENOPIS, HEADQUARTERED IN SAN DIEGO, CALIFORNIA (USA)
GENOPIS EXPERTISE IN PLASMID DNA TECHNOLOGY EXPANDS WACKER S PORTFOLIO AS A CONTRACT MANUFACTURER FOR THE PHARMACEUTICAL INDUSTRY
PURCHASE PRICE CONSISTS OF A $39 MILLION UPFRONT PAYMENT AND FURTHER PERFORMANCE-RELATED PAYMENTS
CEO RUDOLF STAUDIGL: ACQUISITION EXPANDS WACKER S PORTFOLIO AND CAPACITIES AND CREATES A PRESENCE IN THE IMPORTANT US BIOPHARMA MARKET Munich / San Diego, February 3, 2021 - The Munich-based chemical company WACKER is acquiring 100 percent of the shares in pharmaceutical contract manufacturer Genopis Inc. from Helixmith Co Ltd, Seoul (South Korea) and Medivate Partners LLC, Seoul (South Korea). WACKER signed a corresponding agreement today. WACKER will continue Genopis existing customer relationships as a
Results from phase 3 gene therapy trial for diabetic peripheral neuropathy published online by Clinical and Translational Science
Share Article
VM202 (donaperminogene seltoplasmid) is a first-in-class, proprietary, non-viral, potentially regenerative plasmid DNA gene therapy. The Phase 3 study for painful DPN, led by Professor John (Jack) Kessler at Northwestern University, was conducted in two parts, one for 9 months (VMDN-003; 500 subjects) and one with a 3-month extension to 12 months (VMDN-003b; 101 subjects). This is the first gene therapy phase 3 trial that has ever been done for pain. Phase 3 data, published in Clinical and Translational Science, present latest clinical outcomes for VM202 (Engensis) in painful diabetic peripheral neuropathy (DPN), suggesting excellent safety and promising efficacy. VMDN-003 study achieved safety endpoints, while VMDN-003b showed clinically meaningful pain reduction vs. placebo. Safety and tolerability of Engensis continues to appear hig